Sat, Oct 25, 2014, 8:42 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • techbrokers techbrokers Oct 15, 2006 10:32 PM Flag

    What pipeline ?

    <<The valuation of $24 I think is a stretch>>

    Maybe, may be not. J&J unit's willing to market Dacogen indicates that market for the drug is very significant, at least from their estimate. Based on current estimate, world wide sale of $400 mil(Dacogen) is a very moderate estimate. So, SUPG will have at least $100 mil/annual. Annual expense will not be over $15 mil after getting rid of these marketing and executives starting next year. This translates profit $85 mil/year. 20 times earnings is very moderate for valuation. So, market cap of SUPG will be around $1.7 bil, about $30/share.

    If you don't think Dacogen sale will not reach $400 WW, J$J Cilag must be an idiot for licensing a drug having less than $150 sale outside of NA (since MGI estimate $250 for NA which look like conservative now).

    Dacogen's pipeline possibly worths nothing at this moment. CLIMB is a technology, but its potential needs to be proved and validated.

8.4950.000(0.00%)Oct 10 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
SodaStream International Ltd.
NasdaqGSFri, Oct 24, 2014 4:00 PM EDT
Digital River Inc.
NasdaqGSFri, Oct 24, 2014 4:00 PM EDT